Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics

Area of Science:

• Pharmaceutical policy
• Intellectual property law
• Global health equity

Background:

• Patent pools for Fixed Dose Combination (FDC) antiretroviral drugs (ARVs) are essential for addressing urgent public health needs in underserved markets.
• Originator companies express concerns that patent pooling may create exploitable opportunities for generic competitors, potentially undermining patent holder rights.

Purpose of the Study:

• To analyze the concerns of the pharmaceutical brand industry regarding ARV patent pools.
• To propose a strategy for an equitable global market that eliminates discrimination between end-users in high-income and resource-limited countries.
• To advocate for prioritizing public health needs over profit-driven policies in ARV access.

Main Methods:

• Analysis of originator company concerns regarding patent pooling for antiretroviral drugs.
• Exploration of strategies to foster equitable access to medicines.
• Review of international health policy recommendations and trade agreements.

Main Results:

• Delayed patent pools for second and third-line FDC ARVs pose a significant risk to public health in underserved regions.
• A proposed strategy involves initial partnerships between originator companies for rapid FDC ARV availability, followed by patent pool negotiations with generic manufacturers.
• This approach aligns with global health recommendations and international trade principles against protectionism.

Conclusions:

• Urgent implementation of patent pools for FDC ARVs is necessary to meet critical public health demands.
• A collaborative strategy prioritizing health over profit can ensure equitable access to essential ARVs worldwide.
• The proposed patent pool strategy supports global health equity and international trade commitments.